North, E., et al. “Observations on the Sensitivity of Staphylococci to Penicillin.” Medical Journal of Australia 2 (1945): 44–46.
O’Neill, L. A. “Immunity’s Early-Warning System.” Scientific American, January 2005.
Osler, W. S. The Principles and Practice of Medicine, Designed for the Use of Practitioners and Students of Medicine. New York: Appleton, 1923.
Paget, S. Pasteur and After Pasteur. London: A&C Black, 1914.
Parke, Davis & Company. Therapeutic Notes, Vol. 1. Detroit: Parke, Davis & Company, 1894.
Payne, D. J. “Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery.” Nature Reviews—Drug Discovery 6, no. 1 (January 2007): 29–42.
Peterson, A. F. Pharmaceutical Selling, “Detailing,” and Sales Training, 2nd ed. Scarsdale, NY: Heathcote-Woodbridge, 1959.
Podolsky, S. H. The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics. Baltimore, MD: Johns Hopkins University Press, 2015.
Porter, E. “A Dearth of Innovation for Key Drugs.” New York Times, July 23, 2014, B1.
Pringle, P. Experiment Eleven: Dark Secrets Behind the Discovery of a Wonder Drug. New York: Walker & Co., 2012.
Raoult, D., et al. “The History of Epidemic Typhus.” Infectious Disease Clinics in North America 18, no. 1 (March 2004): 127–40.
Rasmussen, N. “The Moral Economy of the Drug Company-Medical Scientist Collaboration in Interwar America.” Social Studies of Science 34 (2004): 161–85.
Rasmussen, N. “The Drug Industry and Clinical Research in Interwar America: Three Types of Physician Collaborator.” Bulletin of the History of Medicine 79 (2005): 50–80.
Ravina, E. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. New York: John Wiley & Sons, 2011.
Reichl, R. “The F.D.A.’s Blatant Failure on Food.” New York Times, July 30, 2014.
Reilly, G. W. The FDA and Plan B: The Legislative History of the Durham-Humphrey Amendments and the Consideration of Social Harms in the Rx-OTC Switch (May 12, 2006). LEDA at Harvard Law School. Retrieved June 28, 2015. dash.harvard.edu/bitstream/handle/1/8965550/Reilly06.html?sequence=2.
Richards, A. “Production of Penicillin in the United States (1941–1946).” Nature 201 (February 1964): 441–45.
Richards, A. N. “Remarks Concerning the Relations Between Universities, Industry and Government with Respect to Medical Research.” The Clinical Problems of Advancing Years (March 16, 1949).
Riethmiller, S. “Ehrlich, Bertheim, and Atoxyl: The Origins of Modern Chemotherapy.” Bulletin of the History of Chemistry 23 (1999): 28–33.
Robbins, L. Louis Pasteur and the Hidden World of Microbes. Oxford: Oxford University Press, 2001.
Rodengen, J. L. The Legend of Pfizer. Fort Lauderdale, FL: Write Stuff Syndicate, 1999.
Rolleston, J. “Venereal Disease in Literature.” British Journal of Venereal Disease 10, no. 3 (1934): 147–74.
Roosevelt, F. D. Executive Order 8807 Establishing the Office of Scientific Research and Development (June 28, 1941). The American Presidency Project. Retrieved December 14, 2014. www.presidency.ucsb.edu/ws/index.php?pid=16137#.
Root-Bernstein, R. S. “How Scientists Really Think.” Perspectives in Biology and Medicine 32, no. 4 (Summer 1987): 473–89.
Root-Bernstein, R. S. Discovering: Inventing and Solving Problems at the Frontiers of Scientific Knowledge. Cambridge, MA: Harvard University Press, 1989.
Rosen, W. The Most Powerful Idea in the World: A Story of Steam, Industry, and Invention. New York: Random House, 2010.
Rosenberg, C. E. “The Therapeutic Revolution: Medicine, Meaning and Social Change in Nineteenth Century America.” Perspectives in Biology and Medicine 20, no. 4 (Summer 1977): 485–506.
Roth, K. H. Development and Production of Synthetic Gasoline. Translated by Nicholas Levis. I. G. Farbenindustrie AG in World War II (2011). Retrieved March 8, 2015. www.wollheim-memorial.de/en/entwicklung_und_produktion_von_synthetischem_benzin.
Rothman, S. The Pursuit of Perfection: The Promise and Perils of Medical Enhancement. New York: Vintage Books, 2004.
Rothman, S. M. Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History, 1st ed. Baltimore, MD: Johns Hopkins University Press, 1995.
Roy, A., et al. “Effect of BCG Vaccination Against Mycobacterium tuberculosis Infection in Children: Systematic Review and Meta-analysis. British Medical Journal 349, no. g4643 (August 2014): 1–11.
Sarrett, L. H. Max Tishler 1906–1989: A Biographical Memoir. Washington, DC: National Academies Press, 1995.
Saturday Review. Letters to the Editor. Saturday Review, January 24, 1959, 21–23.
Schatz, A. “The True Story of the Discovery of Streptomycin.” Actinomycetes 4, no. 2 (August 1993): 27–39.
Seppa, N. “Low-Tech Bacteria Battle.” Science News, October 4, 2014, 22–26.
Sexton, P. Legends of Literature: The Best Articles, Interviews, and Essays from the Archives of Writer’s Digest Magazine. New York: Writer’s Digest Books, 2007.
Shaw, G. The Doctor’s Dilemma, Getting Married, & the Shewing-Up of Blanco Posnet. London: Constable & Co., 1947.
Sheehan, J., et al. “The Fire That Made Penicillin Famous.” Yankee Magazine, November 1982, 125–203.
Silberman, C. E. “Drugs: The Pace Is Getting Furious.” Forbes, May 1960, 140.
Silcox, H. “Production of Penicillin.” Chemical Engineering News 24, no. 20 (October 1946): 2762–64.
Silverman, M., et al. Pills, Profits, and Politics. Berkeley: University of California Press, 1974.
Smith, I. Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence. Clinical Microbiology Reviews 16, no. 3 (July 2003): 463–96.
Smith, M. Overview of Benzene-Induced Aplastic Anaemia. European Journal of Haemotology—Supplementum 60 (1996): 107–10.
Starr, P. The Social Transformation of American Medicine: The Rise of a Sovereign Profession and the Making of a Vast Industry. New York: Basic Books, 1984.
Steen, K. The American Synthetic Organic Chemicals Industry: War and Politics, 1910–1930. Charlotte: University of North Carolina Press, 2014.
Stephens, T., et al. Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. New York: Basic Books, 2001.
Stevenson, W. “Charles Pfizer.” In W. J. Hausman, Immigrant Entrepreneurship: German American Business Biographies 1720 to the Present, Vol. 2. Washington, DC: German Historical Institute, 2014.
Swann, J. P. Academic Scientists and the Pharmaceutical Industry. Baltimore, MD: Johns Hopkins University Press, 1988.
Swann, J. P. “FDA and the Practice of Pharmacy: Prescription Drug Regulation Before the Durham-Humphrey Amendment of 1951.” Pharmacy in History 36, no. 2 (1994): 55–70.
Tager, M. “John F. Fulton, Coccidioidomycosis, and Penicillin.” Yale Journal of Biology and Medicine 49 (June 1976): 391–98.
Temin, P. Taking Your Medicine: Drug Regulation in the United States. Cambridge, MA: Harvard University Press, 1980.
Thagard, P. “The Concept of Disease: Structure and Change.” Communication and Cognition 29 (1996): 445–78.
Thomas, L. The Youngest Science: Notes of a Medicine Watcher. New York: Viking, 1983.
Tillitt, M. H. “Army-Navy Pay Tops Most Civilians’ Unmarried Private’s Income Equivalent to $3,600 Salary.” Barron’s National Business and Financial Weekly, April 24, 1944.
Tishler, M. Interview with Max Tishler. By L. G. Heitzman. November 14, 1983. Philadelphia: Chemical Heritage Society.
Tocqueville, A. de. Reflections: The Revolutions of 1848. New Brunswick, NJ: Transaction Publishers, 1987.
Todar, K. “Mycobacterium tuberculosis and Tuberculosis.” Todar’s Online Textbook of Bacteriology (2008–2012). Retrieved March 13, 2015. textbookof
bacteriology.net/tuberculosis_3.html.
Todd, A., et al. Perspectives in Organic Chemistry. New York: Interscience Publishers, 1956.
University of Pennsylvania. “Penicillin and the American Public.” Health, Medicine, and American Culture 1930–1960 (2002). Retrieved March 6, 2015. ccat.sas.upenn.edu/goldenage/state/pub/sl_pub1.htm.
University of Pennsylvania. “Personal Correspondence: Penicillin.” Health, Medicine, and American Culture 1930–1960 (2002). Retrieved March 6, 2015. ccat.sas.upenn.edu/goldenage/state/pub/letters/sl_pub_letters_index.htm.
Van den Belt, H. Spirochaetes, Serology, and Salvarsan: Ludwig Fleck and the Construction of Medical Knowledge About Syphilis. Wageningen, Netherlands: Grafisch bedrijf Ponsen & Looijen b.v., 1997.
Volansky, R. “Paul Ehrlich: The Man Behind the ‘Magic Bullet.’” HemOnc Today (May 25, 2009).
Waksman, S. A. U. S. Streptomycin and the Process of Preparation, Patent No. 2,449,866, September 21, 1948.
Waksman, S. A. The Conquest of Tuberculosis. Berkeley: University of California Press, 1964.
Waksman, S. A. The Antibiotic Era: A History of the Antibiotics and of Their Role in the Conquest of Infectious Diseases and in Other Fields of Human Endeavor. Tokyo: Selman Foundation of Japan, 1975.
Waller, J. Leaps in the Dark: The Making of Scientific Reputations. Oxford: Oxford University Press, 2004.
Weidel, W., et al. “Bagshaped Macromolecules—A New Outlook on Bacterial Cell Walls.” In F. Nord, Advances in Enzymology and Related Areas of Molecular Biology, Vol. 26. New York: John Wiley & Sons, 2009, 193–223.
Wirth, T., et al. “Origin, Spread and Demography of the Mycobacterium tuberculosis Complex.” PLoS Pathogens 4, no. 9 (September 2008): 1–10.
Witkop, B. “Paul Ehrlich and His Magic Bullets—Revisited.” Proceedings of the American Philosophical Society 143, no. 4 (December 1999): 540–57.
Woese, C. R. “Bacterial Evolution.” Microbiological Reviews 55, no. 2 (1987): 221–71.
Woodward, R. “The Total Synthesis of Vitamin B12.” Pure and Applied Chemistry 33, no. 1 (January 1973): 145–78.
Woytinsky, E., et al. World Population and Production: Trends and Outlook. New York: Twentieth Century Fund, 1953.
Xue, K. “Superbug: An Epidemic Begins.” Harvard Magazine, May–June 2014, 40–49.
Younkin, P. A. Making the Market: How the American Pharmaceutical Industry Transformed Itself During the 1940s. Berkeley, CA: Institute for Research on Labor and Economics, March 2008.
Younkin, P. A. “A Healthy Business: The Evolution of the U.S. Market for Prescription Drugs.” PhD diss., University of California, Berkeley, 2010.
Zachary, G. P. Endless Frontier: Vannevar Bush, Engineer of the American Century. New York: The Free Press, 1997.
Zimmer, C. “We May Be Our Own Best Medicine.” New York Times, September 16, 2014, D7.
INDEX
The page numbers in this index refer to the printed version of this book. The link provided will take you to the beginning of that print page. You may need to scroll forward from that location to find the corresponding reference on your e-reader. Page numbers in italics refer to picture captions.
Abbott Laboratories, 161, 169, 203, 240, 254, 255, 296
Abraham, Edward Penley, 120–21, 126–27, 129, 140–42, 174, 174n, 221, 235, 235n
Achromycin, 226–27
aconite, 242
actinomycetes, 114n, 190–92, 194, 195, 197, 216
see also Streptomyces
actinomycin, 192
adrenaline, 242
Adrian, Edgar, 98n
advertising, 228–29, 258, 267–68, 274, 275, 281
Aesop, 36
Agfa, 57, 62
Aguilar, Abelardo, 238, 240
AIDS, 293–94
Akers, Elva, 129, 132
Albrecht, William, 214
alcohol, 17–19
Alexander, Albert, 129–30, 150
Alexander Fleming and Penicillin (Hughes), 150
Alexander of Tralles, 8
Alien Property Custodian (APC), 159, 160, 169
alkaloids, 158
Allison, V. D., 88
alternate allocation studies, 208–9
alternative medicine, 12, 85n
American Aniline, 160
American Chemical Society, 232
American Cyanamid, 215, 225–27, 227n
American Medical Association (AMA), 73, 75, 249, 252, 256, 262, 274, 275, 281
Journal of the American Medical Association (JAMA), 228–29, 249, 255, 258, 275, 281
American Society of Pharmacology, 222
Amici, Giovanni, 18–19
amine groups, 54
anaphylaxis, 262
anemia, 230, 249
aplastic, 249–52, 254, 258–62, 279, 281
aniline dyes, 46, 47, 52, 54, 64, 158, 244
animal diseases, 184
anthrax, 22–23, 25–27, 35, 202, 224
vaccine for, 26–27
Antibiotic Medicine and Clinical Therapy, 269–71
antibiotics, 72, 92, 139, 152, 155–56, 176, 181, 236–37, 257, 265–74, 297–305
advertising of, 229
animals’ growth accelerated by, 231–37, 302
broad-spectrum, 217, 224–25, 240, 242, 276, 277
coining of word, 192
fixed-dose combination, 213n, 271–73, 279
FTC report on, 276–77
GAIN and, 301, 303, 304
hormetic, 236–37, 251
Kefauver hearings and, 279
macrolide, 238
overuse of, 265–67, 302
poisoning from, 266
quinolone, 299
resistance to, 77–78, 234–37, 264n, 266, 297, 301–4
safety of, 261–63, 302
stewardship programs for, 302
viral diseases and, 266–67, 302
vitamins and, 271
World War II and, 177
Antibiotics and Chemotherapy, 249, 269
antibodies, 43, 44, 48
antigens, 42, 48
antihistamine, 242
antiseptics, 34–36, 67, 87
Antitrust and Monopoly Subcommittee (Kefauver hearings), 277–81, 288, 291
aplastic anemia, 249–52, 254, 258–62, 279, 281
Arrowsmith (Lewis), 208
arsenic, 53–55, 63, 65, 242
arsphenamine (Salvarsan), 55–56, 57–59, 63, 67, 84, 86, 100, 131, 150, 178, 192
ascorbic acid, 199
Aspergillus niger, 138
aspirin, 212
Atabrine, 176, 177
Atiyah, Michael, 105n
atoms, 49–52
atorvastatin, 296
atoxyl, 53–55
atropine, 159
Aureomycin, 216–19, 223–27, 231–34, 236, 237, 254, 272, 274
autopsies, 22
Aventis, 297
azobenzene dyes, 52, 64–66, 68, 70, 102
AZT, 294
Bacillus subtilis, 112
bacteremia, 3
bacteria, 23–25, 28, 36, 41, 236
antibiotic resistance and, 77–78
gram-negative, 94, 181, 192, 194, 217, 218, 237, 244, 298
gram-positive, 94, 174, 175, 190, 194n, 198, 217, 218, 224, 238, 244
oxygen and, 87
reproduction of, 94
soil-dwelling, 23, 24, 129, 132, 190–95, 199, 213, 216–18, 236, 238, 243–44, 263, 274, 301n
type III secretion system in, 237
bacterial pneumonia, 35
Baeyer, Adolf von, 46
&nb
sp; Banting, Frederick, 239
barbiturates, 286
Barker, Thomas Vipond, 142
Barnes, John M., 117
Bartz, Quentin, 244
BASF, 57, 62, 63, 178
battlefield injuries, 86, 87, 163, 167, 178, 180
Bayer, 62–71, 102, 160n, 225, 296, 299n
Bean, William, 257
Beaverbrook, Max Aitken, Lord, 95, 100
Béchamp, Antoine, 52–53
Beecham Limited, 121
Behring, Emil von, 35, 43–47, 57, 62, 63, 104, 215, 242, 296
belladonna, 158, 159, 242, 261
Bell Labs, 162
Benadryl, 242
benzene, 250
Berenblum, Isaac, 109
Bernal, J. D., 144
Bernard, Claude, 26–27, 85n
Bernhauer, Konrad, 137
Bernoulli, Daniel, 14
Bertheim, Alfred, 53–54
Best, Charles, 239
beta-lactam ring, 3, 175, 220–21, 304
Bi-Con, 233
Bigelow, Jacob, 73–74
bile, 7
biofilms, 236
biological warfare, 202–3
Biot, Jean-Baptiste, 16
Bismarck, Otto von, 29, 44
bismuth, 159
Blair, John, 276, 277
blistering, 10
blood, 7
blood dyscrasias, 248–50, 254, 264
bloodletting, 5, 7, 9, 14, 183
Washington and, 5
Blundell, James, 67n
Bohr, Niels, 99n
bone marrow, 250
Boots Pure Drug Company, 173
Bosch, Carl, 62, 63, 178
Boston Globe, 166
Bovet, Daniel, 69–70
Bragg, Lawrence, 143–44
Bragg, William Henry, 143–44
Bristol Laboratories, 225–27, 227n, 240
Bristol-Myers, 244n
Bristol-Myers Squibb, 270, 296, 297
Britain:
army of, 82, 84–86, 119
pharmaceutical industry in, 121–22, 141
Brown, Francis C., 278
bubonic plague, 13, 35, 194, 197, 217, 224, 237
Buchner, Eduard, 26n
Buchner, Hans, 43
Bugie, Elizabeth, 205
Bumstead, John, 1–2
burial alive, 6n
Burkholder, Paul, 243–44